Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Condoliase
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Ferring Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferring Plans FDA Advisory Meeting for SI-6603 in Lumbar Disc Herniation Treatment
Details : SI-6603 (condoliase) is an GAG-degrading enzyme investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH) in adults.
Product Name : SI-6603
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Condoliase
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Ferring Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Conjugated Sodium Hyaluronate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613
Details : The companies will jointly develop SI-613 in China for knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : Diclofenac Conjugated Sodium Hyaluronate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement